A large real-world study found that GLP-1 receptor agonists are associated with sharply lower cardiovascular risks in obese patients with obstructive sleep apnea. Researchers reported reduced incidences of heart failure, pulmonary hypertension, heart attack, and death compared with matched populations not on the drugs. The findings add outcome evidence from observational care settings, where patient selection, adherence, and comorbid burden remain key variables to evaluate. Still, the breadth of endpoints covered suggests clinicians are looking beyond weight loss and glycemic control. For payers and cardiovascular specialists, the study provides new real-world ammunition for assessing GLP-1 use in higher-risk respiratory-metabolic populations.